Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
Related Questions
Do you recommend any alternative schedule for Cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What are your top takeaways in GU Cancers from ESMO 2024?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
How do you manage dysgeusia from Enfortumab Vedotin?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
How do you manage prostate cancer in patients that cannot swallow pills?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
